Targeting MicroRNAs in Cancer: Rationale, Strategies and Challenges

By R. Garzon, Guido Marcucci, Carlo Maria Croce. Nature reviews. Drug discovery, 2010

1,531 citations recorded by the source corpus.

MicroRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs that regulate gene expression. Early studies have shown that miRNA expression is deregulated in cancer and experimental data indicate that cancer phenotypes can be modified by targeting miRNA expression. Based on these observations, miRNA-based anticancer therapies are being developed, either alone or in combination with current targeted therapies, with the goal to improve disease response and increase cure rates. The advantage of using miRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. In this Review, we describe the role of miRNAs in tumorigenesis and critically discuss the rationale, the strategies and the challenges for the therapeutic targeting of miRNAs in cancer.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/963b739add74b8a0267bbfd904bfb5fa3b3f9d29

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “Such modifications included application of nucleotide analogs, backbone modifications and terminal modifications such as addition of inverted bases and biotin or alkyl groups [48,69].”
RNA-based Therapeutics- Current Progress and Future Prospects (2012, background): “The dysregulation of endogenous miRNAs has been linked to numerous diseases, including many types of cancers (Garzon et al., 2010).”
Development of microRNA therapeutics is coming of age (2014, positive): “…genetic gain-or loss-of-function studies of specific miRNAs together with recent data from pharmacological modulation of individual miRNAs or miRNA families in animal disease models implies that miRNAs are viable targets for therapeutics (van Rooij, 2012; van Rooij & Olson, 2012; Stenvang et al ,…”
Hallmarks of cancer: the next generation. (2011, positive): “By now dozens of microRNAs have been implicated in various tumor phenotypes (Garzon et al., 2010), and yet these only scratch the surface of the real complexity, as the functions of hundreds of microRNAs known to be present in our cells and altered in expression in different forms of cancer remain t”
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements (2019, background): “miRNAs a cl ss of small endog nous n -protein coding RNAs that h ve the size of approximatel ~22 nts; they are capable f altering the expression of target genes at the post-transcriptional level, mainly by binding at the 3′UTR region of their mRNA [195].”